Inovio
Inovio is developing synthetic DNA vaccines to prevent and treat cancers and infectious disease. In humans, their SynCon® vaccines delivered using proprietary electroporation technology are generating best-in-class immune responses, with therapeutic T-cells exceeding other technologies in terms of magnitude, breadth, and response rate.